irasia.com - Investor Relations Asia Pacific
HOME

CSPC Pharmaceutical Group Limited
(Formerly known as China Pharmaceutical Group Limited)
(Incorporated in Hong Kong under the Companies Ordinance)

Announcements & Notices       


Please download the latest "Acrobat Reader" to view the PDF.

  • 2022-August-12
  • DATE OF BOARD MEETING (in PDF)
  • 2022-August-4
  • VOLUNTARY ANNOUNCEMENT - MINGFULE (RECOMBINANT HUMAN TNK TISSUE-TYPE PLASMINOGEN ACTIVATOR FOR INJECTION) MET PRIMARY ENDPOINT IN PHASE III STUDY FOR THE TREATMENT OF ACUTE ISCHEMIC STROKE (in PDF)
  • 2022-August-4
  • CHANGE OF ADDRESS OF SHARE REGISTRAR AND TRANSFER OFFICE (in PDF)
  • 2022-August-1
  • LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION (in PDF)
  • 2022-August-1
  • RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR (in PDF)
  • 2022-July-28
  • VOLUNTARY ANNOUNCEMENT - DOCETAXEL FOR INJECTION (ALBUMIN-BOUND) GRANTED ORPHAN-DRUG DESIGNATION BY U.S. FDA FOR TREATMENT OF GASTRIC CANCER (in PDF)
  • 2022-July-28
  • VOLUNTARY ANNOUNCEMENT - EXCLUSIVE LICENSE AGREEMENT FOR SYSA1801 WITH ELEVATION ONCOLOGY, INC. (in PDF)
  • 2022-July-11
  • VOLUNTARY ANNOUNCEMENT - "LACOSAMIDE INJECTION" OBTAINS DRUG REGISTRATION APPROVAL (in PDF)
  • 2022-July-11
  • VOLUNTARY ANNOUNCEMENT - "GABAPENTIN CAPSULES" OBTAINS DRUG REGISTRATION APPROVAL (in PDF)
  • 2022-June-24
  • CONNECTED TRANSACTIONS - LEASE AGREEMENTS (in PDF)
  • 2022-June-22
  • VOLUNTARY ANNOUNCEMENT - BIOLOGIC LICENSE APPLICATION FOR JMT103 ACCEPTED BY THE NMPA (in PDF)
  • 2022-June-13
  • VOLUNTARY ANNOUNCEMENT - "PRAMIPEXOLE DIHYDROCHLORIDE SUSTAINED-RELEASE TABLETS" OBTAINS DRUG REGISTRATION APPROVAL (in PDF)
  • 2022-May-30
  • VOLUNTARY ANNOUNCEMENT - "TENOFOVIR ALAFENAMIDE FUMARATE TABLETS" OBTAINS DRUG REGISTRATION APPROVAL (in PDF)
  • 2022-May-27
  • LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION (in PDF)
  • 2022-May-27
  • APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND CHANGE OF CHIEF EXECUTIVE OFFICER (in PDF)
  • 2022-May-26
  • POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON 26 MAY 2022 (in PDF)
  • 2022-May-25
  • QUARTERLY RESULTS FOR THE THREE MONTHS ENDED 31 MARCH 2022 (in PDF)
  • 2022-May-18
  • VOLUNTARY ANNOUNCEMENT - "DOXOFYLLINE INJECTION" OBTAINS DRUG REGISTRATION APPROVAL (in PDF)
  • 2022-May-13
  • DATE OF BOARD MEETING (in PDF)
  • 2022-May-5
  • VOLUNTARY ANNOUNCEMENT - "DONEPEZIL HYDROCHLORIDE TABLETS" OBTAINS DRUG REGISTRATION APPROVAL (in PDF)
  • 2022-April-28
  • INSIDE INFORMATION - PRINCIPAL FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE THREE MONTHS ENDED 31 MARCH 2022 (in PDF)
  • 2022-April-26
  • VOLUNTARY ANNOUNCEMENT - HIGHLY SELECTIVE FGFR4 INHIBITOR "SYHX2005" OBTAINS CLINICAL TRIAL APPROVAL (in PDF)
  • 2022-April-22
  • VOLUNTARY ANNOUNCEMENT - "ESOMEPRAZOLE SODIUM FOR INJECTION" OBTAINS DRUG REGISTRATION APPROVAL (in PDF)
  • 2022-April-22
  • VOLUNTARY ANNOUNCEMENT - "VORTIOXETINE HYDROBROMIDE TABLETS" OBTAINS DRUG REGISTRATION APPROVAL (in PDF)
  • 2022-April-22
  • VOLUNTARY ANNOUNCEMENT - "NIFEDIPINE CONTROLLED-RELEASE TABLETS" OBTAINS DRUG REGISTRATION APPROVAL (in PDF)
  • 2022-April-21
  • NOTICE OF ANNUAL GENERAL MEETING (in PDF)
  • 2022-April-20
  • VOLUNTARY ANNOUNCEMENT - ANTI-TUMOR NANODRUG "CISPLATIN MICELLE INJECTION" OBTAINS CLINICAL TRIAL APPROVAL (in PDF)
  • 2022-April-3
  • VOLUNTARY ANNOUNCEMENT - COVID-19 mRNA VACCINE "SYS6006" OBTAINS CLINICAL TRIAL APPROVAL (in PDF)
  • 2022-March-22
  • CASH DIVIDEND ANNOUNCEMENT FOR EQUITY ISSUER (in PDF)
  • 2022-March-22
  • ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2021 (in PDF)
  • 2022-March-21
  • VOLUNTARY ANNOUNCEMENT - CLASS 1 NEW DRUG JMT103 MEETS PRE-DEFINED ENDPOINTS IN THE PIVOTAL CLINICAL TRIAL FOR THE TREATMENT OF UNRESECTABLE OR SURGICALLY DIFFICULT GIANT CELL TUMOR OF BONE (in PDF)
  • 2022-March-18
  • VOLUNTARY ANNOUNCEMENT - "DUVELISIB CAPSULES" OBTAINS DRUG REGISTRATION APPROVAL (in PDF)
  • 2022-March-17
  • INSIDE INFORMATION - PRINCIPAL FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE YEAR ENDED 31 DECEMBER 2021 (in PDF)
  • 2022-March-10
  • DATE OF BOARD MEETING (in PDF)
  • 2022-February-8
  • VOLUNTARY ANNOUNCEMENT - ACQUISITION OF EQUITY INTEREST IN RECOMGEN BIOTECH (in PDF)
  • 2022-February-7
  • VOLUNTARY ANNOUNCEMENT - ANTI-TUMOR NANODRUG "SYHA1908 FOR INJECTION" OBTAINS CLINICAL TRIAL APPROVAL (in PDF)
  • 2022-January-27
  • VOLUNTARY ANNOUNCEMENT - JMT601 (CPO107) GRANTED FAST TRACK DESIGNATION BY U.S. FDA FOR TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (in PDF)
  • 2022-January-20
  • VOLUNTARY ANNOUNCEMENT - GRANT OF SHARE AWARDS TO SELECTED GRANTEES BY A SHAREHOLDER (in PDF)
  • 2022-January-12
  • VOLUNTARY ANNOUNCEMENT - "LENVATINIB MESILATE CAPSULES" OBTAINS DRUG REGISTRATION APPROVAL (in PDF)
  • 2022-January-11
  • VOLUNTARY ANNOUNCEMENT - "MITOXANTRONE HYDROCHLORIDE LIPOSOME INJECTION" OBTAINS DRUG REGISTRATION APPROVAL (in PDF)
  • 2022-January-10
  • VOLUNTARY ANNOUNCEMENT - "ZOLEDRONIC ACID INJECTION" OBTAINS DRUG REGISTRATION APPROVAL (in PDF)
  • 2021
  • 2021 Announcements & Notices
  • 2020
  • 2020 Announcements & Notices
  • 2019
  • 2019 Announcements & Notices
  • 2018
  • 2018 Announcements & Notices
  • 2017
  • 2017 Announcements & Notices
  • 2016
  • 2016 Announcements & Notices
  • 2015
  • 2015 Announcements & Notices
  • 2014
  • 2014 Announcements & Notices
  • 2013
  • 2013 Announcements & Notices
  • 2012
  • 2012 Announcements & Notices
  • 2011
  • 2011 Announcements & Notices
  • 2010
  • 2010 Announcements & Notices
  • 2009
  • 2009 Announcements & Notices
  • 2008
  • 2008 Announcements & Notices
  • 2007
  • 2007 Announcements & Notices
  • 2006
  • 2006 Announcements & Notices


  • Company's Index
  • irasia.com

  • About irasia.com   |   Terms of Use   |   Disclaimer
    © Copyright 1996-2022 irasia.com Ltd. All rights reserved.
    DISCLAIMER:
    irasia.com Ltd. makes no guarantee as to the accuracy or completeness of any information provided on this website. Under no circumstances shall irasia.com Ltd. be liable for damages resulting from the use of the information provided on this website.